Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

William J. Sandborn, Brian G. Feagan, Colleen Marano, Hongyan Zhang, Richard Strauss, Jewel Johanns, Omoniyi J. Adedokun, Cynthia Guzzo, Jean Frederic Colombel, Walter Reinisch, Peter R. Gibson, Judith (Judy) Collins, Gunnar Järnerot, Toshifumi Hibi, Paul Rutgeerts

Research output: Contribution to journalArticle

433 Citations (Scopus)

Abstract

Background & Aims Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional treatment. Methods We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of 1064 adults with UC (Mayo score: 6-12; endoscopic subscore ≥2; 774 patients in phase 3). Patients were randomly assigned to groups given golimumab doses of 100 mg and then 50 mg (phase 2 only), 200 mg and then 100 mg, or 400 mg and then 200 mg, 2 weeks apart. The phase 3 primary end point was week-6 clinical response. Secondary end points included week-6 clinical remission, mucosal healing, and Inflammatory Bowel Disease Questionnaire (IBDQ) score change. Results In phase 2, median changes from baseline in the Mayo score were -1.0, -3.0, -2.0, and -3.0, in the groups given placebo, 100 mg/50 mg, 200/100 mg, and 400/200 mg golimumab, respectively. In phase 3, rates of clinical response at week 6 were 51.0% and 54.9% among patients given 200 mg/100 mg and 400 mg/200 mg golimumab, respectively, vs 30.3% among those given placebo (both, P ≤.0001). Rates of clinical remission and mucosal healing and mean changes in IBDQ scores were significantly greater in both golimumab groups vs the placebo group (P ≤.0014, all comparisons). Rates of serious adverse events were 6.1% and 3.0%, and rates of serious infection were 1.8% and 0.5%, in the placebo and golimumab groups, respectively. One patient in the 400 mg/200 mg group died as a result of surgical complications of an ischiorectal abscess. Conclusions Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo. ClinicalTrials.gov Number: NCT00487539.

Original languageEnglish (US)
Pages (from-to)85-95
Number of pages11
JournalGastroenterology
Volume146
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Ulcerative Colitis
Placebos
Inflammatory Bowel Diseases
Tumor Necrosis Factor-alpha
golimumab
Therapeutics
Abscess
Monoclonal Antibodies
Quality of Life
Infection

Keywords

  • Dose-Response
  • Human Monoclonal Antibody
  • Inflammatory Bowel Disease
  • TNF Antagonist

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Sandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., ... Rutgeerts, P. (2014). Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology, 146(1), 85-95. https://doi.org/10.1053/j.gastro.2013.05.048

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. / Sandborn, William J.; Feagan, Brian G.; Marano, Colleen; Zhang, Hongyan; Strauss, Richard; Johanns, Jewel; Adedokun, Omoniyi J.; Guzzo, Cynthia; Colombel, Jean Frederic; Reinisch, Walter; Gibson, Peter R.; Collins, Judith (Judy); Järnerot, Gunnar; Hibi, Toshifumi; Rutgeerts, Paul.

In: Gastroenterology, Vol. 146, No. 1, 01.2014, p. 85-95.

Research output: Contribution to journalArticle

Sandborn, WJ, Feagan, BG, Marano, C, Zhang, H, Strauss, R, Johanns, J, Adedokun, OJ, Guzzo, C, Colombel, JF, Reinisch, W, Gibson, PR, Collins, JJ, Järnerot, G, Hibi, T & Rutgeerts, P 2014, 'Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis', Gastroenterology, vol. 146, no. 1, pp. 85-95. https://doi.org/10.1053/j.gastro.2013.05.048
Sandborn, William J. ; Feagan, Brian G. ; Marano, Colleen ; Zhang, Hongyan ; Strauss, Richard ; Johanns, Jewel ; Adedokun, Omoniyi J. ; Guzzo, Cynthia ; Colombel, Jean Frederic ; Reinisch, Walter ; Gibson, Peter R. ; Collins, Judith (Judy) ; Järnerot, Gunnar ; Hibi, Toshifumi ; Rutgeerts, Paul. / Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. In: Gastroenterology. 2014 ; Vol. 146, No. 1. pp. 85-95.
@article{b728ed1e32ea4902a19bb5c73e0fc378,
title = "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis",
abstract = "Background & Aims Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-na{\"i}ve patients with moderate-to-severe UC despite conventional treatment. Methods We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of 1064 adults with UC (Mayo score: 6-12; endoscopic subscore ≥2; 774 patients in phase 3). Patients were randomly assigned to groups given golimumab doses of 100 mg and then 50 mg (phase 2 only), 200 mg and then 100 mg, or 400 mg and then 200 mg, 2 weeks apart. The phase 3 primary end point was week-6 clinical response. Secondary end points included week-6 clinical remission, mucosal healing, and Inflammatory Bowel Disease Questionnaire (IBDQ) score change. Results In phase 2, median changes from baseline in the Mayo score were -1.0, -3.0, -2.0, and -3.0, in the groups given placebo, 100 mg/50 mg, 200/100 mg, and 400/200 mg golimumab, respectively. In phase 3, rates of clinical response at week 6 were 51.0{\%} and 54.9{\%} among patients given 200 mg/100 mg and 400 mg/200 mg golimumab, respectively, vs 30.3{\%} among those given placebo (both, P ≤.0001). Rates of clinical remission and mucosal healing and mean changes in IBDQ scores were significantly greater in both golimumab groups vs the placebo group (P ≤.0014, all comparisons). Rates of serious adverse events were 6.1{\%} and 3.0{\%}, and rates of serious infection were 1.8{\%} and 0.5{\%}, in the placebo and golimumab groups, respectively. One patient in the 400 mg/200 mg group died as a result of surgical complications of an ischiorectal abscess. Conclusions Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo. ClinicalTrials.gov Number: NCT00487539.",
keywords = "Dose-Response, Human Monoclonal Antibody, Inflammatory Bowel Disease, TNF Antagonist",
author = "Sandborn, {William J.} and Feagan, {Brian G.} and Colleen Marano and Hongyan Zhang and Richard Strauss and Jewel Johanns and Adedokun, {Omoniyi J.} and Cynthia Guzzo and Colombel, {Jean Frederic} and Walter Reinisch and Gibson, {Peter R.} and Collins, {Judith (Judy)} and Gunnar J{\"a}rnerot and Toshifumi Hibi and Paul Rutgeerts",
year = "2014",
month = "1",
doi = "10.1053/j.gastro.2013.05.048",
language = "English (US)",
volume = "146",
pages = "85--95",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

AU - Sandborn, William J.

AU - Feagan, Brian G.

AU - Marano, Colleen

AU - Zhang, Hongyan

AU - Strauss, Richard

AU - Johanns, Jewel

AU - Adedokun, Omoniyi J.

AU - Guzzo, Cynthia

AU - Colombel, Jean Frederic

AU - Reinisch, Walter

AU - Gibson, Peter R.

AU - Collins, Judith (Judy)

AU - Järnerot, Gunnar

AU - Hibi, Toshifumi

AU - Rutgeerts, Paul

PY - 2014/1

Y1 - 2014/1

N2 - Background & Aims Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional treatment. Methods We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of 1064 adults with UC (Mayo score: 6-12; endoscopic subscore ≥2; 774 patients in phase 3). Patients were randomly assigned to groups given golimumab doses of 100 mg and then 50 mg (phase 2 only), 200 mg and then 100 mg, or 400 mg and then 200 mg, 2 weeks apart. The phase 3 primary end point was week-6 clinical response. Secondary end points included week-6 clinical remission, mucosal healing, and Inflammatory Bowel Disease Questionnaire (IBDQ) score change. Results In phase 2, median changes from baseline in the Mayo score were -1.0, -3.0, -2.0, and -3.0, in the groups given placebo, 100 mg/50 mg, 200/100 mg, and 400/200 mg golimumab, respectively. In phase 3, rates of clinical response at week 6 were 51.0% and 54.9% among patients given 200 mg/100 mg and 400 mg/200 mg golimumab, respectively, vs 30.3% among those given placebo (both, P ≤.0001). Rates of clinical remission and mucosal healing and mean changes in IBDQ scores were significantly greater in both golimumab groups vs the placebo group (P ≤.0014, all comparisons). Rates of serious adverse events were 6.1% and 3.0%, and rates of serious infection were 1.8% and 0.5%, in the placebo and golimumab groups, respectively. One patient in the 400 mg/200 mg group died as a result of surgical complications of an ischiorectal abscess. Conclusions Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo. ClinicalTrials.gov Number: NCT00487539.

AB - Background & Aims Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF) -α, for treatment of ulcerative colitis (UC). We evaluated subcutaneous golimumab induction therapy in TNF-α antagonist-naïve patients with moderate-to-severe UC despite conventional treatment. Methods We integrated double-blind phase 2 dose-finding and phase 3 dose-confirmation trials in a study of 1064 adults with UC (Mayo score: 6-12; endoscopic subscore ≥2; 774 patients in phase 3). Patients were randomly assigned to groups given golimumab doses of 100 mg and then 50 mg (phase 2 only), 200 mg and then 100 mg, or 400 mg and then 200 mg, 2 weeks apart. The phase 3 primary end point was week-6 clinical response. Secondary end points included week-6 clinical remission, mucosal healing, and Inflammatory Bowel Disease Questionnaire (IBDQ) score change. Results In phase 2, median changes from baseline in the Mayo score were -1.0, -3.0, -2.0, and -3.0, in the groups given placebo, 100 mg/50 mg, 200/100 mg, and 400/200 mg golimumab, respectively. In phase 3, rates of clinical response at week 6 were 51.0% and 54.9% among patients given 200 mg/100 mg and 400 mg/200 mg golimumab, respectively, vs 30.3% among those given placebo (both, P ≤.0001). Rates of clinical remission and mucosal healing and mean changes in IBDQ scores were significantly greater in both golimumab groups vs the placebo group (P ≤.0014, all comparisons). Rates of serious adverse events were 6.1% and 3.0%, and rates of serious infection were 1.8% and 0.5%, in the placebo and golimumab groups, respectively. One patient in the 400 mg/200 mg group died as a result of surgical complications of an ischiorectal abscess. Conclusions Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo. ClinicalTrials.gov Number: NCT00487539.

KW - Dose-Response

KW - Human Monoclonal Antibody

KW - Inflammatory Bowel Disease

KW - TNF Antagonist

UR - http://www.scopus.com/inward/record.url?scp=84890620601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890620601&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2013.05.048

DO - 10.1053/j.gastro.2013.05.048

M3 - Article

C2 - 23735746

AN - SCOPUS:84890620601

VL - 146

SP - 85

EP - 95

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -